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Abstract
Norovirus (NoV) is now the dominant aetiological agent of acute gastroenteritis, and, with the recent introduction of rotavirus vaccines in
many countries, this is likely to remain the case. NoV has a signiﬁcant impact on human wellbeing in terms of morbidity, economic costs and
mortality in developing countries. NoVs are divided into six genogroups (GI–GVI), but only GI, GII and GIV are known to infect humans,
with GII being the most prevalent, causing >95% of human infections. The immune system is thought to drive selection of emerging
pandemic NoVs through both antigenic drift and shift. This phenomenon results in the replacement of dominant circulating viruses
approximately every 3 years, with new variants able to re-infect hosts previously infected with earlier viruses. This review explores the
evolutionary aspects of contemporary NoVs.
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Introduction
In 1929, hyperemesis hemis or winter-vomiting disease was
ﬁrst documented by Zahorsky [1] as an illness characterized
by sudden-onset vomiting and diarrhoea, the prevalence of
which peaked during the winter seasons. Many years later, we
now know that this illness was caused by a single-stranded
RNA virus, which is now termed norovirus (NoV). NoV is
now estimated to cause half of all cases of gastroenteritis
globally [2].
Pandemic forms of NoV cause substantial morbidity [3–5],
mortality [2] and economic costs [6,7] across the globe each
year. The human immune system drives selection and antigenic
change in NoV, resulting in replacement of circulating dom-
inant viruses every 2–3 years, with new variants able to
re-infect hosts immune to earlier viruses. This pattern of
displacement is likely to continue with a rising incidence of
NoV infections worldwide [8,9].
Recently, the identiﬁcation of a new genogroup II, geno-
type 4 (GII.4) pandemic NoV in 2012 was soon followed by a
global pandemic that started around November 2012, and
affected >1.2 million people in the UK that winter alone and
many millions more across the globe [10]. For the ﬁrst time, a
novel GII.4 variant (Sydney 2012) was identiﬁed prior to it
causing a pandemic of gastroenteritis, leading to global
awareness, which triggered preventive strategies in institu-
tional settings [10]. In this review, the genetic mechanisms and
immunological factors underlying patterns of NoV evolution
are explored.
NoV is highly infectious [11] and is transmitted primarily
from person to person within closed settings such as schools,
cruise ships, hospitals, child-care facilities, and institutions for
the elderly [12,13]. The clinical symptoms of NoV include
acute onset of nausea, vomiting, headaches, chills, abdominal
cramps, and loose or watery diarrhoea [14], usually lasting for
2–4 days [15]. Viral shedding lasts for several weeks beyond
the symptomatic phase, with a decline in the number of
viruses excreted [16,17]. The morbidity and mortality rates of
NoV infection are high in groups such as young children, the
elderly, and immunosuppressed and immunocompromised
patients [8,18,19]. Outbreaks of viral gastroenteritis are
difﬁcult to control, and lead to considerable economic costs,
owing to closure of hospital wards, facilities, and businesses,
ª2014 The Authors
Clinical Microbiology and Infection ª2014 European Society of Clinical Microbiology and Infectious Diseases
REVIEW 10.1111/1469-0691.12746
including the food retail, oyster and cruise ship industries
[6,7].
NoV is a member of the family Caliciviridae, and as such is a
small, round virion 28–35 nm in diameter. It possesses a
single-stranded, positive-sense, polyadenylated RNA genome of
c. 7.5 kb divided into three open reading frames (ORFs). ORF1,
which makes up the ﬁrst two-thirds of the genome, and is >5 kb
in length, encodes seven non-structural (NS) proteins involved
in replication of the genome. These include an N-terminal
protein (NS1-2 of unknown function), an NTPase (NS3), p22 of
unknown function (NS4), a viral genome-linked protein (NS5), a
3C-like protease (NS6), and an RNA-dependent RNA poly-
merase (NS7) (55, 127) [15]. Two structural proteins—VP1,
the major capsid protein, and VP2, whose function is uncertain
—are encoded by ORF2 and ORF3, respectively. NoVs are
divided into six genogroups (GI–GVI), but only GI, GII and GIV
are known to infect humans, with GII being the most prevalent
(>95% of NoV infections). Genogroups are further classiﬁed
into numerous capsid genotypes differing at the nucleotide level
by c. 15%. The term ‘variant’ is only used for individual viruses
within the pandemic GII.4 lineages [20].
Molecular Epidemiology of NoVs
Although >32 different human NoV genotypes have been
identiﬁed [20], GII.4 is the only genotype associated with
global pandemics of gastroenteritis, and viruses belonging to
this genetic lineage account for >80% of all human NoV
infections at any one time [8,9]. Owing to the lack of an ex vivo
cultivation system for human NoV, it has been extremely
difﬁcult to determine why GII.4 viruses are so successful, and
many aspects of the NoV replication cycle and evolution
remain unknown. What gives GII.4 viruses such epidemiolog-
ical potency is currently an active research area within the ﬁeld
[21]. GII.4 viruses have caused all six major NoV pandemics of
acute gastroenteritis in the last two decades. These six
pandemic GII.4 variants include US 96, which caused a
pandemic in the late 1990s [22,23], Farmington Hills 2002
[24,25], Hunter 2004 [26], Den Haag 2006b [9,27], New
Orleans 2009 [28] and, most recently, Sydney 2012 [29,30].
Of the six pandemic GII.4 variants, the ﬁrst four probably
evolved from previous GII.4 viruses through mutations within
the protruding (P) domain of the capsid (antigenic drift)
[31–33]. However, interestingly, the most recent two GII.4
pandemic variants, New Orleans 2009 and Sydney 2012, show
both antigenic capsid variation and GII.4 intragenotype
recombination at the ORF1–ORF2 overlap, and have therefore
evolved through processes involving both antigenic drift and
antigenic shift [30].
Importantly, the emergence of novel NoV GII.4 variants
coincided with dramatic increases in the rate of NoV infection
and epidemics of gastroenteritis across the globe. This was
exempliﬁed by the current pandemic GII.4 variant, Syd-
ney 2012 [10]. Sydney 2012 was ﬁrst identiﬁed in March
2012 in Australia [30], and by August 2012 it was responsible
for c. 25% of NoV-associated acute gastroenteritis outbreaks
in Australia [29]. However, between November 2012 and
January 2013, it rapidly and simultaneously replaced the
previously dominant GII.4 NoV, New Orleans 2009, in
Australia and New Zealand [29], Asia [34], Europe
[10,35,36], Canada [37], and the USA [38], leading to an
increase in the number of outbreaks of gastroenteritis across
the globe. Sydney 2012 is currently the prevalent NoV in the
world, although, on the basis of previous evolutionary patterns
of GII.4 emergence, we would expect this situation to last for
only another 1–2 years before it is replaced by another GII.4
variant.
Pre-epidemic forms of NoV GII.4 Variants
Interestingly, studies have revealed that the pre-epidemic
forms of New Orleans 2009 (Orange 2008, GQ845367) and
Sydney 2012 (Auckland 2010, KF060124) were in circulation
for up to 2 years prior to their global epidemic spread
[27,29,37,39]. Speciﬁcally, pre-epidemic Sydney 2012 viruses
were identiﬁed in New Zealand in 2010 [29], and in Canada
[37] and Italy [39] in 2011. Notably, these pre-epidemic viruses
were associated with limited outbreaks, and did not have
a global prevalence. Analysis of the key P2 antigenic epi-
topes A–E of Sydney 2012 revealed that several changes were
required before the pre-epidemic form achieved pandemic
potential [29]. This suggests that novel GII.4 variants circulate
at low levels in the population before acquiring the necessary
P2 mutations to escape herd immunity. Such mutations
probably facilitate their emergence as a pandemic viruses.
This implies that the newly emergent GII.4 variants could be
monitored and detected long before they evolve into new
variants that have escaped herd immunity. Vaccines could
therefore be produced before a pandemic of acute gastroen-
teritis arises.
Antigenic Drift Results in New pandemic
GII.4 NoV Variants
A number of mechanisms drive the evolution of the GII.4
lineage [21]. GII.4 viruses are thought to be able to bind to
a wider range of histo-blood group antigens, which are
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carbohydrate attachment factors for NoV, than viruses of
other NoV genotypes, and therefore have a larger susceptible
population to infect [40,41]. Additionally, the higher epide-
miological ﬁtness of this lineage of viruses could be the result
of higher replication and mutation rates giving them a greater
capacity to evolve than other NoV genotypes [31].
Antigenic variation is an important factor contributing to
the emergence of novel NoVs, with most variation being
observed between different GII.4 variants localized to ﬁve
evolving blockade epitopes (A–E) within the capsid P2 domain
[42,43]. Epitope A is believed to be the most important
determinant of antigenic change, following the isolation and
mapping of human-derived antibodies to this site with a
surrogate neutralization assay [44]. Through the accumulation
of mutations at these ﬁve sites, NoV is able to generate new
antigenic variants of the pandemic GII.4 lineage that have the
potential to escape herd immunity [31,45]. These factors
explain why the P2 domain is therefore under the greatest
selective pressure [43,45,46]. As an example, if we look at P2
changes between the previous dominant GII.4 pandemic
variant, New Orleans 2009, and the current circulating GII.4
variant, Sydney 2012, four sites within the P2 domain (294,
368, 373, and 376) were identiﬁed with novel variant-speciﬁc
mutations, and these residues were subject to signiﬁcant
positive selection [29]. Two of these sites (294 and 368) lie in
epitope A, and one (376) in epitope C; another site (373) was
not associated with an epitope. It is therefore possible that the
adaptive changes at these sites contributed to the emergence
of Sydney 2012. This is consistent with work by Debbink et al.
[47], who showed, using both monoclonal antibodies and
human-derived polyclonal sera, that Sydney 2012 was antigen-
ically distinct from New Orleans 2009. Furthermore, muta-
tional studies showed that residues 294 and 368 were critical
determinants of the speciﬁc antigenicity of Sydney 2012 [47],
and were indeed two of four residues shown to be under
positive selection, as mentioned above [29].
There is now substantial evidence that immune selection
drives NoV capsid evolution, and results in the displacement of
dominant NoVs by new emerging viruses that have antigenic
regions within the capsid that are not susceptible to the
current circulating herd immunity.
Recombination in NoV
RNA recombination is one of the major driving forces of viral
evolution, and is a powerful mechanism for creating large
changes in the viral genome. The ability of RNA polymerases
to switch templates [48] facilitates the development of
recombinant RNA viruses with altered functional properties,
and thereby contributes to the evolution of viruses. The
naming of NoV recombinants can be confusing; good guidelines
for general NoV nomenclature are outlined in [20]. Recom-
bination in NoV could have signiﬁcant implications for escape
from humoral cytotoxic T-lymphocyte immune responses to
NS proteins, although, to date, this has not been studied. The
majority of intergenotype and intragenotype recombination in
NoV occur at a single location, the ORF1–ORF2 overlap
[49,50], which is also the transcription start site for the viral
subgenomic RNA. A secondary recombination breakpoint lies
within the ORF2–ORF3 junction in GII.4 viruses [30]. The
ORF1–ORF2 breakpoint is of interest, as it separates the NS
region responsible for replication of the virus from the
structural region that encodes the capsid. In effect, recombi-
nation at this junction allows the virus to exchange its viral
capsid while retaining the region involved in viral genome
replication. Such recombination could therefore also aid in
escape from herd immunity.
Interestingly, nearly all contemporary non-GII.4 NoVs are
recombinant viruses, and they include recombinant types such
as GIIPb/GII.3, GII.Pb/GII.13, GII.Pg/GII.12, GII.P4/GII.10,
GII.P6/GII.14, and GII.P16/GII.2. In a recent study in Singapore,
of all of the non-GII.4 NoVs identiﬁed, only the GII.6 and GII.7
genotypes were wild-type, non-recombinant viruses [51]. The
GII.Pb/GII.3 variant is one of the most prevalent NoVs in
circulation. This variant caused hundreds of outbreaks of
gastroenteritis across Europe in 2000 and 2001 [52–54], and
subsequent outbreaks across Australasia [23] and Asia [55,56].
Unlike GII.4 variants, which are replaced every few years,
GII.Pb/GII.3 NoVs are still prevalent today in children [57,58].
Since the emergence of the GII.Pb/GII.3 variant, the GII.b
polymerase has undergone further recombination events, and
has, to date, been associated with ﬁve different capsid
genotypes, i.e. GII.1, GII.2, GII.3, GII.4, and GII.13 [51,59],
none of which is likely to contain the GII.b polymerase original
capsid sequence. Nonetheless, this also shows the prominent
role of recombination in the evolution of NoVs prevalent in
children. Interestingly, in a recent study, the GII.P16/GII.2
variant, which was identiﬁed in 2010, was more prevalent than
the older GII.Pb/GII.3 variant [51], and this virus was also was
also identiﬁed predominantly in children. This could suggest a
displacement and an end to the >10 years of prevalence of
recombinant GII.Pb/GII.3 viruses in childhood infections.
A genome-wide approach to reconstruct recombination in
the pandemic GII.4 viruses was undertaken with a view to
determine evolutionary patterns within them [30]. This
revealed the widespread impact of both intergenotype and
intragenotype recombination on the emergence of many of the
12 main GII.4 variants, including the two most recent: New
Orleans 2009 and Sydney 2012. A total of 11 potential
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recombination events were detected within the GII.4 viruses
examined, and nine were located near the ORF1–ORF2
overlap (between positions 5085 and 5100) [30]. Of the 12
main GII.4 viruses identiﬁed since 1996, half show signs of
intragenotypic recombination [30]. It has been shown that the
ORF1 region of Sydney 2012 was derived from Osaka 2007
(GPe/GII.4), whereas the ORF2–ORF3 region is related to
Apeldoorn 2008 (GII.4). Both of these ancestral GII.4 variants
caused epidemics, but they were not associated with wide-
spread gastroenteritis pandemics. However, recombination
between these ‘lesser’ two GII.4 viruses nonetheless resulted
in the emergence of a pandemic strain, demonstrating the
signiﬁcance of antigenic shift for NoV evolution.
Conclusions
In summary, NoV is a signiﬁcant human pathogen that imposes
both a health burden and an economic burden on all societies.
Its continual evolution though antigenic drift and shift means
that this is likely to continue, given that antiviral agents against
NoV are in their infancy [60,61], and that vaccines are only in
the early phases of clinical trials [62].
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